These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30674687)

  • 81. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 82. New quadrivalent HPV vaccine developments.
    Tovar JM; Bazaldua OV
    Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cost-Effectiveness Study of HPV Vaccination as a Primary Prevention Strategy for Anal Cancer in HIV-Positive Men in Chile.
    Vargas Parada C; Lennert Veerman J
    Value Health Reg Issues; 2016 Dec; 11():17-23. PubMed ID: 27986194
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review.
    Pham CT; Juhasz M; Sung CT; Mesinkovska NA
    J Am Acad Dermatol; 2020 Jan; 82(1):202-212. PubMed ID: 31085272
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [HPV vaccination in Germany Low vaccination rates endanger prevention goals].
    MMW Fortschr Med; 2009 Dec; 151(51-52):44-5. PubMed ID: 20088323
    [No Abstract]   [Full Text] [Related]  

  • 86. Clinical and economic burden of HPV-related cancers in the US veteran population.
    Saxena K; Dawson RS; Cyhaniuk A; Bello T; Janjan N
    J Med Econ; 2022; 25(1):299-308. PubMed ID: 35156867
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States.
    Wu CF; Xu L; Fu S; Peng HL; Messick CA; Lairson DR
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1156-1164. PubMed ID: 30362917
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Economic burden of human papillomavirus-related diseases in Italy.
    Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
    PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.
    Hartwig S; Syrjänen S; Dominiak-Felden G; Brotons M; Castellsagué X
    BMC Cancer; 2012 Jan; 12():30. PubMed ID: 22260541
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
    Righolt CH; Pabla G; Mahmud SM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy.
    Mennini FS; Panatto D; Marcellusi A; Cristoforoni P; De Vincenzo R; Di Capua E; Ferrandina G; Petrillo M; Sasso T; Ricci C; Trivellizzi N; Capone A; Scambia G; Gasparini R
    Clin Ther; 2011 Aug; 33(8):1084-1095.e4. PubMed ID: 21788076
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.
    Koleva D; De Compadri P; Padula A; Garattini L
    Intern Emerg Med; 2011 Apr; 6(2):163-74. PubMed ID: 21312004
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability?
    McRee AL; Reiter PL; Chantala K; Brewer NT
    Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):1937-44. PubMed ID: 20647398
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Incidence, psychosocial burden, and economic impact of genital warts in Mexico.
    Domenech-Viñolas M; León-Maldonado L; Ramírez-Palacios P; Flores YN; Granados-García V; Brown B; Corona E; Liu S; Lazcano-Ponce E; Salmerón J
    Salud Publica Mex; 2018; 60(6):624-632. PubMed ID: 30699267
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Provinces weighing HPV vaccination of boys.
    Eggertson L
    CMAJ; 2012 Mar; 184(5):E250-1. PubMed ID: 22371513
    [No Abstract]   [Full Text] [Related]  

  • 96. UK needs vaccine to protect against HPV types causing recurrent respiratory papillomatosis.
    Rothera MP; Albert DM; Hughes OR
    BMJ; 2011 Oct; 343():d6672. PubMed ID: 22008803
    [No Abstract]   [Full Text] [Related]  

  • 97. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.
    Hampl M; Huppertz E; Schulz-Holstege O; Kok P; Schmitter S
    BMC Infect Dis; 2011 Mar; 11():73. PubMed ID: 21426562
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The spectrum and clinical sequelae of human papillomavirus infection.
    Monk BJ; Tewari KS
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S6-13. PubMed ID: 18499914
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Monitoring of human papillomavirus vaccination.
    Dillner J; Arbyn M; Unger E; Dillner L
    Clin Exp Immunol; 2011 Jan; 163(1):17-25. PubMed ID: 21062269
    [TBL] [Abstract][Full Text] [Related]  

  • 100. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions?
    Elst L; Albersen M
    Semin Oncol Nurs; 2022 Jun; 38(3):151284. PubMed ID: 35577640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.